<DOC>
	<DOC>NCT02670746</DOC>
	<brief_summary>The objective of the study is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma in the Netherlands. Additional objectives are to monitor the incidence and reversibility of neuropathy during treatment, to assess the patient's Quality of life when treated with nab-paclitaxel/gemcitabine and to evaluate the use of resources that come with treating metastatic pancreatic cancer.</brief_summary>
	<brief_title>A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients over 18 years of age who understand and voluntarily sign an informed consent form. Patients treated for pancreatic adenocarcinoma. Patients currently treated for metastatic pancreatic cancer with other therapy than nabpaclitaxel plus gemcitabine Refusal to participate in the study. Women who are pregnant or breastfeeding. Hypersensitivity to the active substance or to any of the excipients. Participation in interventional trials during the period of treatment with nabpaclitaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Observational</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Netherlands</keyword>
	<keyword>Quality of Life</keyword>
</DOC>